Peringatan Keamanan

L-phenylalanine will exacerbate symptoms of phenylketonuria if used by phenylketonurics. L-phenylalanine was reported to exacerbate tardive dyskinesia when used by some with schizophrenia.

Phenylalanine

DB00120

small molecule approved investigational nutraceutical

Deskripsi

Phenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.

Struktur Molekul 2D

Berat 165.1891
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Absorbed from the small intestine by a sodium dependent active transport process.

Metabolisme

Hepatic. L-phenylalanine that is not metabolized in the liver is distributed via the systemic circulation to the various tissues of the body, where it undergoes metabolic reactions similar to those that take place in the liver.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

488 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Phenylalanine.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylalanine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Phenylalanine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Phenylalanine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Phenylalanine.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Phenylalanine.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Phenylalanine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Phenylalanine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Phenylalanine.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenylalanine.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Phenylalanine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Phenylalanine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Phenylalanine.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Phenylalanine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Phenylalanine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Phenylalanine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Phenylalanine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Phenylalanine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Phenylalanine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Phenylalanine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Phenylalanine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Phenylalanine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Phenylalanine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Phenylalanine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Phenylalanine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Phenylalanine.
Flunisolide The risk or severity of adverse effects can be increased when Phenylalanine is combined with Flunisolide.
Bortezomib The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bortezomib.
Cladribine Phenylalanine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carmustine.
Amsacrine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Amsacrine.
Bleomycin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bleomycin.
Chlorambucil The risk or severity of adverse effects can be increased when Phenylalanine is combined with Chlorambucil.
Raltitrexed The risk or severity of adverse effects can be increased when Phenylalanine is combined with Raltitrexed.
Mitomycin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mitomycin.
Bexarotene The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bexarotene.
Vindesine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vindesine.
Floxuridine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Floxuridine.
Indomethacin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Indomethacin.
Tioguanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tioguanine.
Vinorelbine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vinorelbine.
Dexrazoxane The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexrazoxane.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Phenylalanine is combined with Beclomethasone dipropionate.
Sorafenib The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sorafenib.
Streptozocin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Streptozocin.
Trifluridine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trifluridine.
Gemcitabine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Gemcitabine.
Betamethasone The risk or severity of adverse effects can be increased when Phenylalanine is combined with Betamethasone.
Teniposide The risk or severity of adverse effects can be increased when Phenylalanine is combined with Teniposide.
Epirubicin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Epirubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Phenylalanine is combined with Chloramphenicol.
Lenalidomide The risk or severity of adverse effects can be increased when Phenylalanine is combined with Lenalidomide.
Altretamine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Altretamine.
Zidovudine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Zidovudine.
Cisplatin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cisplatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Oxaliplatin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cyclophosphamide.
Vincristine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vincristine.
Fluorouracil The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluorouracil.
Propylthiouracil The risk or severity of adverse effects can be increased when Phenylalanine is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methotrexate.
Carbamazepine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carbamazepine.
Vinblastine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Phenylalanine is combined with Linezolid.
Imatinib The risk or severity of adverse effects can be increased when Phenylalanine is combined with Imatinib.
Triamcinolone The risk or severity of adverse effects can be increased when Phenylalanine is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Phenylalanine is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Daunorubicin.
Irinotecan The risk or severity of adverse effects can be increased when Phenylalanine is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Phenylalanine is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Phenylalanine is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Phenylalanine is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Phenylalanine is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Phenylalanine is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Phenylalanine is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Phenylalanine is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Phenylalanine is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Phenylalanine is combined with Melphalan.

Target Protein

Tyrosine 3-monooxygenase TH
Tyrosine aminotransferase TAT
Large neutral amino acids transporter small subunit 2 SLC7A8
Phenylalanine--tRNA ligase alpha subunit FARSA
Phenylalanine-4-hydroxylase PAH
Phenylalanine--tRNA ligase, mitochondrial FARS2
Phenylalanine--tRNA ligase beta subunit FARSB

Referensi & Sumber

Synthesis reference: Gerald L. Bachman, "Recovery of L-phenylalanine and L-aspartic acid during preparation of .alpha.-L-aspartyl-L-phenylalanine methyl ester." U.S. Patent US4348317, issued January, 1967.

Contoh Produk & Brand

Produk: 234 • International brands: 0
Produk
  • 2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose
    Solution • - • Intravenous • Canada • Approved
  • 2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Clinimix
    Solution • - • Intravenous • Canada • Approved
  • 2.5% Travasol Amino Acid Injection Without Electrolytes In 10% Dextrose Quickmix
    Solution • - • Intravenous • Canada • Approved
  • 2.5%travasol Amino Acid InJ.W.eleC.W.25%dex
    Liquid • - • Intravenous • Canada • Approved
  • 2.75% Travas. Amino Acid InJ.W.elecw.25%dex
    Liquid • - • Intravenous • Canada • Approved
  • 2.75% Travasol Amino Acid Injection With Electrolytes In 25% Dextrose Quickmix
    Solution • - • Intravenous • Canada • Approved
  • 2.75% Travasol Amino Acid Injection With Electrolytes In 5% Dextrose Quickmix
    Solution • - • Intravenous • Canada • Approved
  • 2.75%travasol Amino Acid InJ.W.eleC.W.5%dex.
    Liquid • - • Intravenous • Canada • Approved
Menampilkan 8 dari 234 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul